BROFAROMINE IN TREATMENT-RESISTANT DEPRESSED-PATIENTS - A COMPARATIVE TRIAL VERSUS TRANYLCYPROMINE

被引：21

作者：

VOLZ, HP

FALTUS, F

MAGYAR, I

MOLLER, HJ

机构：

[1] PSYCHIAT UNIV HOSP PRAHA, PRAGUE, CZECH REPUBLIC

[2] PSYCHIAT UNIV HOSP BUDAPEST, BUDAPEST, HUNGARY

来源：

JOURNAL OF AFFECTIVE DISORDERS | 1994年 / 30卷 / 03期

关键词：

BROFAROMINE; TRANYLCYPROMINE; TREATMENT RESISTANT DEPRESSION; CONTROLLED CLINICAL TRIAL; SELECTIVE AND REVERSIBLE INHIBITOR OF MAO (TYPE-A);

D O I：

10.1016/0165-0327(94)90081-7

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

In a controlled clinical inpatient trial (n = 93) comparing the efficacy and safety of brofaromine versus tranylcypromine for 6 weeks in treatment-resistant major depressed patients, the two drugs were found to be of comparable afficacy and tolerability. The response rate (a 50% reduction) on the Hamilton Scale for Depression (HAMD) in both groups was about 73%. The most common side effects in the brofaromine group were sleep disorders, hypotension, tremor and dryness of mouth; and in the tranylcypromine group sleep disorders, fatigue, hypotension, tremor and vertigo. Methodological and practical clinical implications of the results are discussed.

引用

页码：209 / 217

页数：9

共 31 条

[1]

American Psychiatric Association, 1984, DIAGN STAT MAN MENT

[2]

DEMONTIGNY C, 1983, ARCH GEN PSYCHIAT, V40, P1327

[3]

FISCHER EK, 1990, MUNCH MED WOCHENS S1, V132, P21

[4] A RATING SCALE FOR DEPRESSION [J].